US FDA approves Revolution Medicines' pancreatic cancer drug

RVMD•2026-08-26

FDA approves targeted pancreatic cancer drug

Aug. 26 (Reuters) - The U.S. Food and Drug Administration approved Revolution Medicines' RVMD.O targeted drug for metastatic pancreatic cancer, the regulator said on Wednesday.

US FDA approves Revolution Medicines' pancreatic cancer drug

FDA approves targeted pancreatic cancer drug

Related News

Last but not least

Victory Capital strikes $7 billion deal for First Eagle Investments; shares rise

Meta falls after $16.68 billion settlement with US states on social media harms

Texas Attorney General Secures Over $1 Billion In Settlement With Meta

Meta reaches $16.68 billion settlement over social media case